	medRxiv preprint doi: https://doi.org/10.1101/2023.05.25.23289996; this version posted May 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
1	TITLE
2	Comparative analysis of symptom profile and risk of death associated with infection by SARS-CoV-2
3	and its variants in Hong Kong
4	
5	AUTHORS
6	
7	Kin On KWOK <sup>1,2,3,*,#</sup> , Wan In WEI <sup>1,*</sup> , Edward B. MCNEIL <sup>1</sup> , Arthur TANG <sup>4</sup> , Julian Wei Tze TANG <sup>5</sup> ,
8	Samuel Yeung Shan WONG <sup>1,@</sup> , Eng Kiong YEOH <sup>6,@</sup>
9	
10	<sup>1</sup> JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
11	Special Administrative Region, China
12	<sup>2</sup> Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong
13	Kong Special Administrative Region, China
14	<sup>3</sup> Hong Kong Institute of Asia-Pacific Studies, The Chinese University of Hong Kong, Hong Kong
15	Special Administrative Region, China
16	<sup>4</sup> School of Science, Engineering and Technology, RMIT University, Vietnam
17	<sup>5</sup> Respiratory Sciences, University of Leicester, Leicester, United Kingdom; Clinical Microbiology,
18	Leicester Royal Infirmary, Leicester, United Kingdom
19	<sup>6</sup> Centre for Health Systems and Policy Research, The Chinese University of Hong Kong, Hong Kong
20	Special Administrative Region, China
21	* Joint first author
22	<sup>@</sup> Joint senior author
23	*Correspondence : kkokwok@cuhk.edu.hk
24	
25	KEYWORDS

26 COVID-19; variants; symptom profile; symptomatology

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 27 ABSTRACT

28 Introduction: The recurrent multi-wave nature of COVID-19 necessitates updating its symptomatology. 29 Before the omicron era, Hong Kong was relatively unscathed and had a low vaccine uptake rate among 30 the old-old, giving us an opportunity to study the intrinsic severity of SARS-CoV-2 variants. A 31 comparison of symptom patterns across variants and vaccination status in Hong Kong has yet to be 32 undertaken. The intrinsic severity of variants and symptoms predictive of severe outcomes are also 33 understudied as COVID-19 evolves. We therefore aim to characterize the effect of variants on symptom 34 presentation, identify the symptoms predictive and protective of death, and quantify the effect of 35 vaccination on symptom development.

Methods: With the COVID-19 case series in Hong Kong from inception to 25 August 2022, an iterative
multi-tier text-matching algorithm was developed to identify symptoms from free text. Cases were fully
vaccinated if they completed two doses. Multivariate regression was used to measure associations
between variants, symptom development, death and vaccination status. A least absolute shrinkage and
selection operator technique was used to identify a parsimonious set of symptoms jointly associated with
death.

42 **Results**: Overall, 70.9% (54450/76762) of cases were symptomatic. We identified a wide spectrum of 43 symptoms (n=102), with cough, fever, runny nose and sore throat being the most common (8.16-47.0%). 44 Intrinsically, the wild-type and delta variant caused similar symptoms, with runny nose, sore throat, itchy 45 throat and headache more frequent in the delta cohort; whereas symptoms were heterogeneous between the wild-type and omicron variant, with seven symptoms (fatigue, fever, chest pain, runny nose, sputum 46 47 production, nausea/vomiting and sore throat) more frequent in the omicron cohort. With full vaccination, 48 omicron was still more likely than delta to cause fever. Fever, blocked nose and shortness of breath were 49 robustly jointly predictive of death as the virus evolved. Number of vaccine doses required for reduction in occurrence varied by symptoms. 50

Discussion: This is the first large-scale study to evaluate the changing symptomatology by COVID-19
 variants and vaccination status using free-text reporting by patients. We substantiate existing findings that Page 2 of 21

- 53 omicron has a different clinical presentation compared to previous variants. Syndromic surveillance can
- 54 be bettered with reduced reliance on symptom-based case identification, increased weighing on
- 55 symptoms robustly predictive of mortality in outcome prediction, strengthened infection control in care
- 56 homes through universal individual-based risk assessment to enable early risk stratification, adjusting the
- 57 stockpile of medicine to tally with the changing symptom profiles across vaccine doses, and
- 58 incorporating free-text symptom reporting by patients.
- 59
- 60 Word count = 404

#### 61 **INTRODUCTION**

62

#### 63 Evolving SARS-CoV-2 epidemiology in Hong Kong

64

65 Hong Kong has experienced five waves of Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The first two waves were driven by the 66 67 ancestral wild-type virus, the third and the fourth were dominated by lineages B.1.1.63 and B.1.36.27, 68 respectively, and the early fifth wave was mainly caused by the omicron subvariant BA.2 [1]. Hong Kong 69 was relatively unscathed in the first four waves, which can be attributed to a hospital-based approach 70 under which all confirmed or suspected cases were isolated. Before the fifth wave, Hong Kong was 71 characterized by a low proportion (18%) of the old-old completing a two-dose primary vaccination series 72 and predominantly vaccine-induced immunity at the population level [2]. To cope with the surge in cases 73 during the fifth wave, an online declaration system was established for the community to self-report their 74 infection and symptoms [3]. Against this background, the disease progression in Hong Kong enables 75 revisiting the clinical spectrum of SARS-CoV-2 of primary infection episodes across vaccination groups 76 amid a changing landscape of viral pathogenicity [4].

77

78 Importance of identifying the symptom profile of SARS-CoV-2

79

80 The recurrent multi-wave nature of COVID-19 [5] makes it worth updating the symptomatology to 81 improve disease recognition, particularly when it involves the telltale signs of severe health outcomes. As 82 of 26 March 2023, weekly hospitalizations by COVID-19 exceeded that of influenza by 13-fold in the 83 United Kingdom [6]. Though symptoms triggered by respiratory illnesses are generally alike [7], the 84 persistent clinical sequelae after the acute phase of infection [8] and the complexity of symptoms added 85 by the omicron variant [9] highlight the need to differentiate COVID-19 from other respiratory diseases. While the circulating omicron variant may induce less severe symptoms than its preceding counterparts 86 87 [10], this benignity can be counterbalanced by an increased incidence of infection disrupting society via

289996; this version posted May 28, 2023. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2023.05 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. sickness. In fact, 46% of the patients infected with omicron regarded their illnesses as moderate or severe 88 89 [11]. 90 91 Research gaps 92 93 Despite the importance of updating symptom profiles and disease burden as SARS-CoV-2 evolves, there 94 are **four** research gaps that need addressing. 95 96 First, symptom profiles of COVID-19 vary across regions [12], but to our knowledge, we are not aware 97 of any study comparing symptom patterns of infection across variants and vaccination status in Hong 98 Kong. Such a clinical spectrum was studied initially [13,14], but the varying pathogenicity of SARS-CoV-2 [4] highlights the need to revisit the clinical presentation. Even under the same viral condition, 99 100 symptom profiles vary with the host properties and the immunity level of the affected population, which 101 is an interplay between natural infection and vaccine regimes (for example, the type of vaccine administered and timing of vaccination). 102 103 Second, the intrinsic severity of SARS-CoV-2 variants are understudied and most published studies have 104 returned mixed findings. Intrinsic-severity estimates are indispensable information to plan upcoming 105 106 infection control strategies against the public burden caused by immune-evasive pathogens,

107 compromising the effectiveness of vaccination. On one hand, the intrinsic severity is less for omicron 108 according to Nyberg and colleagues who reported a larger reduction (comparing omicron with delta) in 109 the risk of hospitalization and death in unvaccinated cases than all cases [15], and by Zhang and 110 colleagues who reported no significant difference in the blood profiles of the fully vaccinated and the 111 non/partially vaccinated [16]. On the other hand, Whitaker and colleagues found that omicron cases were 112 more likely to report cold-like symptoms [17]. Therefore, it is important to unravel the intrinsic severity 113 of the concurrent and recent predominant SARS-CoV-2 variant, especially when the mainstream vaccine

- administered in Hong Kong has low efficacy against symptomatic infection of past strains **[18]**, and when
- 115 it takes time for the bivalent vaccine to be taken by the majority of the community.
- 116
- 117 Third, symptoms predictive of severe health outcomes are understudied as COVID-19 evolves. To our 118 knowledge, such information was studied in the wild-type era by Vahey and colleagues who reported that 119 vomiting, dyspnea, altered mental status, dehydration, and wheezing were significantly associated with 120 hospitalization [19]. However, differences in replication and pathogenicity among SARS-CoV-2 variants 121 [4] may present varied symptom-based predictors of mortality. By identifying which symptoms are 122 predictive of severe outcomes, patients can be better triaged for medical procedures and prioritization of

testing.

124

123

125 Fourth, established work based on structured responses of a predefined scope of symptoms might

126 underestimate the prevalence and diversity of symptoms. For example, Vihta and colleagues recorded 12-

127 16 symptoms [20] versus 32 preset symptoms in the ZOE app [21]). In addition, Malden and colleagues

128 showed that free-text data of electronic medical records increased the identification of more cases for

129 each symptom by 29-64% **[22]**.

130

131 *Study aims and significance* 

132

140

In light of the above research gaps, this study makes use of free-text symptom data self-reported by cases to (i) characterize the (intrinsic and post-vaccination, wherever applicable) effect of variants on symptom presentation, (ii) identify the symptoms which are predictive and protective of death across variants, and (iii) quantify the effect of vaccination on symptom development. Following the World Health Organization's end of the "public health emergency of international concern" declaration for COVID-19 [23], future infection control will focus on elderly and high-risk groups such that further investigations into the telltale signs of COVID-19 (as it evolves) will guide public health policies during patient triage.

- 141 **METHODS**
- 142
- 143 Data curation
- 144
- We analyzed the case series of COVID-19 infections provided by the Centre for Health Protection (CHP)
  between 23 January 2020 and 25 August 2022 from which the following information was available: age,
  sex, chronic diseases, case classification (local or imported), date of case reporting to the CHP, symptoms
  experienced at the date of reporting, date of symptom onset, and vaccination date and type. The symptom
  data was initially solicited by nurse interviews, which was replaced with self-reporting on 26 February
  2022.
- 152 Iterative process of symptom extraction from free-text data
- 153

Symptoms were recorded in the form of free text in addition to four hard-coded symptoms (fever, chest 154 pain, shortness of breath and breathing difficulty). Through compiling frequent lay-person descriptions 155 by cases, a list was created to map their responses to standardized variables created based on the national 156 ambulatory medical care survey (NAMCS) [24]. Classification by NAMCS was based on patients' 157 expression of their symptoms serving as the input to health services, which fits the current context of 158 COVID-19 cases reporting their symptoms. To increase the accuracy of symptom identification, an 159 160 iterative multi-tier text-matching algorithm was developed (Table S1). A sample of 200 randomly 161 selected cases was manually reviewed for symptom extraction to assess the accuracy of this algorithm.

162

163 *Classification of variants* 

164

165 Cases reported on or before 30 June 2020 were regarded as wild-type cases [1]. Starting from the third
166 wave (1 July 2020), cases not sequenced for the determination of the variant or failed/had insufficient

medRxiv preprint doi: https://doi.org/10.1101/2023.05 289996; this version posted May 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. viral load for sequencing were unclassified. For the remaining cases, the variant was determined based on 167 the results of whole genome sequencing by CHP upon positive results of polymerase chain reaction or 168 rapid antigen testing. 169 170 Definition of vaccination status 171 172 Cases were defined as unvaccinated if they did not receive any dose of vaccine on or before the symptom 173 174 onset date (for symptomatic individuals) or the report date (for asymptomatic individuals). Cases were 175 considered to complete a vaccine dose if that dose was received at least 14 days before the symptom 176 onset date (for symptomatic individuals) or the report date (for asymptomatic individuals). Cases were 177 defined as fully vaccinated if they completed two vaccine doses. A 14-day window period was assumed 178 by convention as the human immune system takes time to build up protection [25]. 179 Statistical analysis 180 181 182 Cases with incomplete data were excluded from the analysis (Figure 1). Descriptive statistics, including proportions with binomial confidence intervals, were used to summarize the data. Multivariate regression 183 models were fit to examine (i) the effect of variants on symptom development, (ii) the association of 184 185 symptoms on elderly deaths, and (iii) the effect of vaccination on symptom development. The intrinsic severity of COVID-19 variants among elderly cases, measured as the occurrence of death within 28 days 186 of symptom onset, was compared with Cox's proportional hazards regression. All models were adjusted 187 188 for age, sex, and reporting delay, defined as the time elapsed between symptom onset and the report date for symptomatic cases. When considering the overall effect regardless of variants, the analyses were also 189 190 adjusted for variants. Adjusted odds ratios (aOR) and hazard ratios with 95% confidence intervals (CI) 191 were presented visually.

192

We used a least absolute shrinkage and selection operator (LASSO) technique under the generalized
linear regression framework to identify parsimonious symptoms jointly associated with death. The *glmnet*package in R was used to fit these models [26]. The value of the regularization parameter was determined
using *k*-fold cross validation. The performance of these regression models was evaluated using the area
under the receiver operating characteristic curve (AUC). All analyses were performed in R (version 4.2).
RESULTS

- 200
- 201 Subject characteristics
- 202
- 203 As of 25 August 2022, there were 1,479,393 COVID-19 cases reported in Hong Kong, among which 76,762 were included in the analysis with the majority being BA.2 cases (Figure 1). The reporting period 204 of these cases ranged from 23 January 2020 to 19 July 2022. The study population consisted largely of 205 206 adults aged 20-59 years (74.2%), followed by the elderly aged  $\geq 60$  years (15.3%) and young adults or minors (10.5%) (Table 1). The variant-specific proportion of local cases differed, ranging from over 95% 207 208 for omicron (BA.2) and delta to 34.5% for wild type. All 1,175 wild-type cases were recorded on or before 30 June 2020, while the variants were mostly recorded in 2022. All wild-type cases were 209 210 unvaccinated, but the circulation of its variants or sub-variants was amid an increasing level of vaccine-211 induced population immunity.
- 212
- 213 *Prevalence of symptoms*
- 214

The majority (70.9%) of the cases were symptomatic (Table 1). Compared with the hard-coded
symptoms, extraction from free-text data identified an additional 5336/11343 (47.0%) cases with fever,
714/2173 (32.9%) cases with shortness of breath or breathing difficulty, and 68/1770 (3.8%) with chest
pain. Overall, a wide spectrum of 102 symptoms was identified, among which 30 symptoms had an

219 overall prevalence of at least 0.5% (**Table S3**). The free-text extraction showed that cases used varied

expressions to describe their symptoms in the throat (for example, dry throat, itchy throat, sore throat,
throat discomfort, throat irritation, tonsillitis) and in the muscle pain category (for example, bodyache,
back pain, low extremity pain, unspecified muscle pain) (**Table S2**). Regardless of variants and
vaccination status, the most common symptoms were cough (range: 22.5-47.0%), fever (17.9-37.2%),
runny nose (8.16-33.1%), sore throat (15.0-29.1%) and headache (4.96-14.6%) (**Figure 2**). Among the
wild-type cases, three more symptoms stood out: disturbance of taste and/or smell (6.38%), shortness of
breath (5.19%) and diarrhea (4.94%).

227

#### 228 Effect of variant on symptom presentation

229

230 Effects of variant on symptom presentation were examined among the unvaccinated symptomatic cases (Figure 3), implicating the intrinsic severity of the variants in context. Omicron was more likely than 231 wild-type to be associated with fatigue (aOR: 2.83 [95% CI: 1.53-5.21]), fever (aOR: 1.96 [1.69-2.27], 232 233 chest pain (aOR:7.21 [2.96, 17.6]), runny nose (aOR: 1.36 [1.09-1.69]), expectoration (aOR: 2.54 [1.62-3.99], nausea/vomiting (aOR:5.13 [2.53-10.39]) and sore throat (aOR: 1.68 [1.41-2.00], but less likely to 234 235 be associated with malaise, blocked nose, cough, diarrhea, throat discomfort, taste/smell disturbances, and headache. On the other hand, the symptoms associated with delta and the wild-type were more alike 236 237 in that delta was more likely to be associated with only four symptoms: runny nose (aOR: 4.15 [2.30-7.49]), sore throat (aOR: 1.94 [1.08-3.48]), itchy throat (aOR: 36.58 [3.20-418.78]) and headache (aOR: 238 2.41 [1.24-4.68]). Differences in symptom presentation were also noted between omicron and delta for 239 240 fever, runny nose, and headache.

241

242 Effects of variant on symptom presentation were examined among the fully vaccinated symptomatic

cases (Figure 4). Omicron was more likely than delta to be associated with fever (aOR:1.66 [1.08-2.57]),

but less likely to be associated with malaise, cough, runny nose, dry throat, taste/smell disturbances,

- 245 dizziness, chest discomfort, palpitations (not shown in Figure 4) and headache.
- 246

#### 247 Association between symptom presentation and death

248

209	alleviating symptom presentation was examined among symptomatic elderly cases ( <b>Figure 5</b> ). Receipt of
269	years) (Figure S2), and older age is a significant risk factor for death, the extent of vaccination
268	Considering the difference in symptom presentation between the young (<60 years) and the elderly ( $\geq$ 60
267	
266	Effect of vaccination on symptom presentation
265	
264	(AUC: 0.926).
263	blocked nose, shortness of breath, and fever. The predictive power of these sets of symptoms was good
262	disorders, sore throat, and loss of appetite. Among omicron cases, the predictive set included only
261	fever were predictive of death while protective symptoms included cough, diarrhea, chest pain, voice
260	predictive of death (Table 3). Overall, abdominal pain, blocked nose, malaise, shortness of breath, and
259	With most decedents being elderly, we searched for a robust set of symptoms which were jointly
258	Older age ( $\geq 60$ years) significantly increased the odds of death for all symptoms (not shown in Table 2).
257	
256	(aOR:0.51 [0.30, 0.84]) and sore throat (aOR:0.43 [0.19, 0.87]) were protective.
255	3.47]) and shortness of breath (aOR:2.25 [1.21, 4.03]) were predictive of death; whereas cough
254	cough (37.3%), shortness of breath (25.3%) and sore throat (10.7%) ( <b>Table 2</b> ). Fever (aOR: 2.04 [1.22,
253	and symptomatic, 18 symptoms were ever reported: fever (64.0%) being the most common, followed by
252	than that attributable to the ancestral wild-type (Figure S1). Among 75 decedents who were unvaccinated
251	symptoms onset) due to delta and omicron infections among elderly were similar, and were both higher
250	fully vaccinated were 1.11% and 0.05% respectively. Intrinsically, the hazard of death (within 28 days of
249	The overall case fatality rate (CFR) was 0.25% (195/76,762), and that among the unvaccinated and the
240	

vaccination did not necessarily reduce the occurrence of symptoms, and in fact was associated with an

- 272 increased chance of developing sore throat and some respiratory symptoms such as blocked nose, cough,
- and runny nose. The number of doses required to reduce individual symptoms also varied, from one dose

- for reducing fever, to two doses for reducing shortness of breath, to three doses for reducing chills. We
- also explored the effect of time elapsed since last vaccination on the occurrence of symptoms predictive
- of death (Figure 6). Compared with the number of doses, time elapsed since vaccination given the same
- 277 number of doses did not alter the chance of occurrence of the predictive symptoms.
- 278

#### 279 DISCUSSION

- 280
- 281 Principal findings
- 282

283 This is the first large-scale study to evaluate variations in symptom presentation by COVID-19 variants 284 and vaccination status using free-text reporting by patients. We substantiate existing findings that omicron has a different clinical presentation compared to previous variants [27]. We identified a wide 285 spectrum of symptoms (n=102) associated with SARS-CoV-2 infection, with the most common ones 286 287 being cough, fever, runny nose and sore throat (8.16-47.0%). Intrinsically, symptoms caused by the wildtype and delta were generally similar, except that runny nose, sore throat, itchy throat and headache were 288 289 more frequent in the delta cohort; whereas symptoms were heterogeneous between the wild-type and omicron, with seven symptoms (fatigue, fever, chest pain, runny nose, sputum production, 290 nausea/vomiting and sore throat) more likely to be experienced by the omicron cohort, and seven 291 292 symptoms (malaise, blocked nose, cough, diarrhea, throat discomfort, taste/smell disturbances, and 293 headache) less likely to occur. Under full vaccination coverage, omicron was still more likely than delta to cause fever. Furthermore, fever, blocked nose and shortness of breath were robustly predictive of death 294 295 even when the wild-type virus evolved to the omicron variant. Though the death rate was much lower in the fully vaccinated cohort, vaccination does not necessarily reduce the occurrence of symptoms, and the 296 297 number of doses required to reduce symptoms varied by individual symptoms.

298

299 *Result implications* 

300

- 301 Our findings have five public health implications.
- 302

First, the weighing of symptom-based predictions of COVID-19 should be reduced. We found a high 303 304 prevalence of upper respiratory tract infections among the predominant omicron cases in wave 5 with 305 differences by vaccination status. This result is consistent with five other studies [9,17,20,21,28]. Furthermore, we found a much lower incidence of "loss of taste and smell", which, in the past, was used 306 as a test-triggering symptom [29,30], in the omicron cohort. These altogether increase the difficulty to 307 308 distinguish COVID-19 with symptom-based testing algorithms. In fact, Fragaszy and colleagues 309 calculated the specificity of such algorithms was as low as 47%-27% [31]. Although symptom-based 310 information is of reduced value to diagnosis, we urge updating the symptom variation in public health 311 messaging as failure to do so will hinder public awareness.

312

313 **Second**, the omicron variant may not be intrinsically less severe than preceding variants such that 314 continued surveillance among vulnerable populations should remain in force. Unlike regions with a high incidence of natural infection prior to the omicron era, such as the United States [32], Hong Kong was 315 316 almost free of infection in the community [13,14] coupled with low vaccine uptake rate among the oldold [2]. This allowed us to study the intrinsic severity of mortality among this disproportionately affected 317 318 group. In contrast to Nyberg and colleagues who reported a larger reduction in the risk of death (from omicron to delta) among unvaccinated cases [15], we identified that the risk of death following SARS-319 320 CoV-2 infection among the unvaccinated elderly was similar between omicron and delta (Table S1). We also found that omicron was more likely to cause fever than delta among unvaccinated symptomatic cases 321 322 (Table S3, Figure 2). The reasons for the aforementioned contrasting findings need further investigation. In addition, when compared with other co-circulating respiratory illnesses, omicron, especially the BA.2 323 324 sublineage, is not intrinsically milder and can be more neuropathogenic [33].

325

Third, symptom-based predictions for death are possible and can help refine infection control policies to
tackle COVID-19 in residential care homes for the elderly (RCHEs). Though a major surge in severe

328 illnesses in RCHEs may be unlikely under a high vaccine or infection coverage [34], the delay in seeking 329 medical care among the elderly [35], the multi-fold increase in mortality among institutionalized elderly [36], and the highest number of incidents attributable to RCHEs in the continual recurrent epidemics [6] 330 331 altogether suggest active syndromic surveillance is needed in RCHEs. Further to the proposed frailty 332 screening to be performed on every aged COVID-19 case to enable early risk stratification [37] and the 333 inclusion of certain underlying health conditions as risk characteristics (such as hypertension [38], 334 dyslipidemia and being bed-bound [39]), symptoms consistently predictive of severe clinical outcomes 335 can be added to this individual-based risk assessment. Further to Ryan and colleagues who showed that 336 severe COVID-19 could be predicted by symptoms in the wild-type era [40], we found certain symptoms 337 (fever and shortness of breath) were robustly predictive of death during the wild-type-to-omicron 338 transition. This finding is consistent with earlier reports in the wild-type era that shortness of breath was predictive of death [19,39]. 339

340

341 Fourth, the stockpile of genus epidemicus should be optimized with the changing symptom profiles across vaccine doses given the long-term battle against COVID-19. In line with existing findings which 342 343 reported changing symptom profiles across vaccine doses [9,28], we found that fever was less common as the number of vaccine doses increased, but some respiratory symptoms were still very common, 344 345 including cough, runny nose, blocked nose and sore throat. Though the effect of vaccines on reducing 346 severe outcomes following infection of COVID-19 is present across variants [41], it does not necessarily 347 lower the occurrence of symptoms with high transmissibility. In line with an early report that virus shedding was initially highest in the upper respiratory tract [13], sore throat and runny nose were shown 348 349 to be associated with higher viral load following infection with SARS-CoV-2 [17]. This suggests that the provision of medicine should be adjusted to suppress viral replication in human bodies with respect to the 350 351 changing symptom profiles, particularly in regions with intense social-mixing like Hong Kong where the 352 number of contacts reached 12.5 per day [42]. In Hong Kong, two antiviral agents (Molnupiravir and Paxlovid) were available to improve clinical outcomes, but their effect on symptom alleviation needs 353 354 further research.

355

356	Fifth, future syndromic surveillance should be enriched by free-text reporting of symptoms by patients.
357	By applying a multi-tier text-matching algorithm on free-text symptom data, we identified a wider
358	disease spectrum, which exceeded the number of symptoms predefined by other studies [17,20,21].
359	Considering the four hard-coded symptoms in our dataset, we showed that a large proportion of
360	identification was contributed by additional free-text data (3.8-47%), which is in line with Malden and
361	colleagues who supplemented structured data of electronic medical records with natural language
362	processing of unstructured data and found 29-64% additional cases for each selected symptoms [22].
363	
364	Study strengths and limitations
365	
366	Clinical characteristics of SARS-CoV-2 were widely studied in the initial phase of the pandemic [43], but
367	comparisons between recent subtypes were sparse and the intrinsic severity of subsequent variants were
368	understudied. This is the first large-scale study which adds to the literature in this understudied area with
369	free-text symptom reporting data from the patient perspective. In addition, unlike existing studies, which
370	inferred the variant type to which a case belonged from the predominating strain circulating in the
371	community at that time [17], we defined our cohort based on confirmed laboratory results, minimizing
372	misclassification bias. However, there are two study limitations which bear mentioning. First, the
373	duration and level of symptoms were not recorded such that we were unable to provide a better
374	understanding of the difference between the same symptoms. Second, caution should be exercised when
375	interpreting differences in symptom across variants, which may be biased by the potential underreporting
376	of patient characteristics in the massive fifth omicron wave during which healthcare resources were
377	stringent and by the changing method of data collection over time.
378	

380

379

Conclusion

Upon achieving herd immunity in the population to halt the exponential spread of SARS-CoV-2 [44], the 381 next item on the agenda is to handle the disease burden caused by the changing symptom profile. Existing 382 surveillance infrastructure should be updated with respect to changing symptomatology and mortality risk 383 384 as SARS-CoV-2 and the population immunity level evolve. Such infrastructure can be bettered with 385 reduced reliance on symptom-based case identification, increased weighing on symptoms robustly predictive of mortality in outcome prediction, strengthened infection control in RCHEs through universal 386 387 individual-based risk assessment to enable early risk stratification, and adjusting the stockpile of 388 medicine to target treatment arising from the changing clinical presentation against the background of 389 changing immunity in the population. In addition, real-time algorithms to incorporate patients' free-text 390 reporting of symptoms should be developed to enrich syndromic surveillance. 391 Word count = 3728392

393

#### 394 ACKNOWLEDGEMENT

395

	396	We would like to	acknowledge supp	oort from Health	and Medical	Research Fund	(reference numbers:
--	-----	------------------	------------------	------------------	-------------	---------------	---------------------

397 INF-CUHK-1, 17160302, 18170312, CID-CUHK-A, COVID1903008), General Research Fund

398 (reference numbers: 14112818, 24104920), Wellcome Trust Fund (reference number: 200861/Z/16/Z)

- and Group Research Scheme of The Chinese University of Hong Kong. This work formed part of the
- 400 doctoral thesis requirements for Wan In WEI.
- 401

#### 402 ETHICAL STATEMENT

- 403 This study was approved by the Survey and Behavioral Research Ethics Committee of The Chinese404 University of Hong Kong (reference: SBRE-19-595).
- 405
- 406 DATA STATEMENT

- 407 The availability of the data set is subject to approval from Hong Kong Centre for Health and Protection,
- 408 Department of Health and relevant government departments.
- 409
- 410 COMPETING INTEREST
- 411 None
- 412
- 413 AUTHORS' CONTRIBUTIONS
- 414 Conceptualized: Kin On KWOK (KOK), Wan In WEI (WIW)
- 415 Data curation: Edward B McNeil (EBM), WIW
- 416 Data analysis: EBM, WIW, KOK
- 417 First draft of the manuscript: WWI, KOK
- 418 Data interpretation: KOK, EBM, WIW
- 419 Manuscript editing: EK YEOH (EKY), Samuel YS WONG (SYSW), EBM, WWI, KOK, Arthur TANG
- 420 (AT), Julian TANG (JT)
- 421 Supervision: EKY, SYSW, KOK
- 422 Provision of critical comments: AT, SYSW, JT, EKY

#### 423 **REFERENCES**

- Wong S-C, Au AK-W, Lo JY-C, Ho P-L, Hung IF-N, To KK-W, Yuen K-Y, Cheng VC-C.
   Evolution and Control of COVID-19 Epidemic in Hong Kong. Viruses 2022 Nov 14;14(11).
   PMID:36423128
- Smith DJ, Hakim AJ, Leung GM, Xu W, Schluter WW, Novak RT, Marston B, Hersh BS. COVID Mortality and Vaccine Coverage Hong Kong Special Administrative Region, China, January 6,
   2022-March 21, 2022. MMWR Morb Mortal Wkly Rep 2022 Apr 15;71(15):545–548.
   PMID:35421076
- 431 3. HKSAR Government. "Declaration System for Individuals Tested Positive for COVID-19 Using
  432 Rapid Antigen Test" launched. 2023. Available from:
  433 https://www.info.gov.hk/gia/general/202203/07/P2022030700768p.htm [accessed Apr 7, 2023]
- Shuai H, Chan JF-W, Hu B, Chai Y, Yuen TT-T, Yin F, Huang X, Yoon C, Hu J-C, Liu H, Shi J,
   Liu Y, Zhu T, Zhang J, Hou Y, Wang Y, Lu L, Cai J-P, Zhang AJ, Zhou J, Yuan S, Brindley MA,
   Zhang B-Z, Huang J-D, To KK-W, Yuen K-Y, Chu H. Attenuated replication and pathogenicity of
   SARS-CoV-2 B.1.1.529 Omicron. Nature 2022 Mar;603(7902):693–699. PMID:35062016
- 5. Dhaliwal M, Small R, Webb D, Cluver L, Ibrahim M, Bok L, Nascimento C, Wang C, Garagic A,
  Jensen L. Covid-19 as a long multiwave event: implications for responses to safeguard younger
  generations. BMJ 2022 Jan 27;376:e068123. PMID:35086910
- 441 6. UK Health Security Agency. Weekly national Influenza and COVID-19 surveillance report Week 13
  442 report (up to week 12 data). 2023 Mar. Available from:
  443 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/11
  444 47550/Weekly Flu and COVID-19 report w13 v2.pdf
- 7. Nypaver C, Dehlinger C, Carter C. Influenza and Influenza Vaccine: A Review. J Midwifery
  Womens Health 2021 Jan;66(1):45–53. PMID:33522695
- 8. Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of
  persistent and new clinical sequelae among adults aged 65 years and older during the post-acute
  phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2022 Feb 9;376:e068414.
  PMID:35140117
- Wang M, Liu Z, Wang Z, Li K, Tian Y, Lu W, Hong J, Peng X, Shi J, Zhang Z, Mei G. Clinical
  characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in
  Shanghai. J Med Virol 2023 Jan;95(1):e28224. PMID:36238984
- Ren S-Y, Wang W-B, Gao R-D, Zhou A-M. Omicron variant (B.1.1.529) of SARS-CoV-2:
  Mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases 2022 Jan 7;10(1):1–
  11. PMID:35071500
- Petersen MS, Í Kongsstovu S, Eliasen EH, Larsen S, Hansen JL, Vest N, Dahl MM, Christiansen
  DH, Møller LF, Kristiansen MF. Clinical characteristics of the Omicron variant results from a
  Nationwide Symptoms Survey in the Faroe Islands. Int J Infect Dis 2022 Sep;122:636–643.
  PMID:35811082
- 461 12. Kadirvelu B, Burcea G, Quint JK, Costelloe CE, Faisal AA. Variation in global COVID-19
  462 symptoms by geography and by chronic disease: A global survey using the COVID-19 Symptom
  463 Mapper. EClinicalMedicine 2022 Mar;45:101317. PMID:35265823
- 464 13. Kwok KO, Huang Y, Tsoi MTF, Tang A, Wong SYS, Wei WI, Hui DSC. Epidemiology, clinical
   Page 18 of 21

- 465 spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region. Respirology 2021
   466 Apr;26(4):322–333. PMID:33690946
- 467 14. Kwok KO, Wei WI, Huang Y, Kam KM, Chan EYY, Riley S, Chan HHH, Hui DSC, Wong SYS,
  468 Yeoh EK. Evolving Epidemiological Characteristics of COVID-19 in Hong Kong From January to
  469 August 2020: Retrospective Study. J Med Internet Res 2021 Apr 16;23(4):e26645. PMID:33750740
- Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL,
  Kall M, Bhatt S, Blomquist P, Zaidi A, Volz E, Aziz NA, Harman K, Funk S, Abbott S, COVID-19
  Genomics UK (COG-UK) consortium, Hope R, Charlett A, Chand M, Ghani AC, Seaman SR,
  Dabrera G, De Angelis D, Presanis AM, Thelwall S. Comparative analysis of the risks of
  hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2)
  variants in England: a cohort study. Lancet 2022 Apr 2;399(10332):1303–1312. PMID:35305296
- 476 16. Zhang J, Chen N, Zhao D, Zhang J, Hu Z, Tao Z. Clinical Characteristics of COVID-19 Patients
  477 Infected by the Omicron Variant of SARS-CoV-2. Front Med 2022 May 9;9:912367.
  478 PMID:35615088
- 479 17. Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, Donnelly CA, Chadeau-Hyam M,
  480 Elliott P. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat
  481 Commun 2022 Nov 11;13(1):6856. PMID:36369151
- Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, Borg R, Schulz
  WL, de Oliveira RD, da Silva PV, de Castro DB, Sampaio V de S, de Albuquerque BC, Ramos
  TCA, Fraxe SHH, da Costa CF, Naveca FG, Siqueira AM, de Araújo WN, Andrews JR, Cummings
  DAT, Ko AI, Croda J. Effectiveness of CoronaVac among healthcare workers in the setting of high
  SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study.
  Lancet Reg Health Am 2021 Sep;1:100025. PMID:34386791
- Vahey GM, Marshall KE, McDonald E, Martin SW, Tate JE, Midgley CM, Killerby ME, Kawasaki
  B, Herlihy RK, Alden NB, Staples JE, Colorado Investigation Team2. Symptom Profiles and
  Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado,
  USA, 2020. Emerg Infect Dis 2021 Feb;27(2):385–395. PMID:33496225
- Vihta KD, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, Rourke E, Cook D, Diamond I,
  Crook D, Clifton DA, Matthews PC, Stoesser N, Eyre DW, Walker AS, COVID-19 Infection
  Survey team. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin
  Infect Dis 2022 Aug 3;76(3):e133–41. PMID:35917440
- Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A,
  Figueiredo JC, Hu C, Molteni E, Canas L, Österdahl MF, Modat M, Sudre CH, Fox B, Hammers A,
  Wolf J, Capdevila J, Chan AT, David SP, Steves CJ, Ourselin S, Spector TD. Symptom prevalence,
  duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of
  omicron and delta variant dominance: a prospective observational study from the ZOE COVID
  Study. Lancet 2022 Apr 23;399(10335):1618–1624. PMID:35397851
- Malden DE, Tartof SY, Ackerson BK, Hong V, Skarbinski J, Yau V, Qian L, Fischer H, Shaw SF,
  Caparosa S, Xie F. Natural Language Processing for Improved Characterization of COVID-19
  Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System.
  JMIR Public Health Surveill 2022 Dec 30;8(12):e41529. PMID:36446133
- World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency
   Committee on the COVID-19 pandemic [Internet]. 2023 [cited 2023 May 14]. Available from:
   https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-

- 510 pandemic
- 511 24. Meads S, McLemore T. The national ambulatory medical care survey: symptom classification. Vital
  512 Health Stat 2 1974 May;(63):1–41. PMID:25093394
- 25. Rennert L, Ma Z, McMahan CS, Dean D. Effectiveness and protection duration of Covid-19
  vaccines and previous infection against any SARS-CoV-2 infection in young adults. Nat Commun
  2022 Jul 8;13(1):3946. PMID:35803915
- 516 26. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via
  517 Coordinate Descent. J Stat Softw 2010 Feb 2;33:1–22.
- 518 27. Looi M-K. How are covid-19 symptoms changing? BMJ 2023 Jan 18;380:3. PMID:36653024
- Marquez C, Kerkhoff AD, Schrom J, Rojas S, Black D, Mitchell A, Wang C-Y, Pilarowski G,
  Ribeiro S, Jones D, Payan J, Manganelli S, Rojas S, Lemus J, Jain V, Chamie G, Tulier-Laiwa V,
  Petersen M, DeRisi J, Havlir DV. COVID-19 Symptoms and Duration of Rapid Antigen Test
  Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron
  BA.1 Periods. JAMA Netw Open 2022 Oct 3;5(10):e2235844. PMID:36215069
- 29. Callejon-Leblic MA, Moreno-Luna R, Del Cuvillo A, Reyes-Tejero IM, Garcia-Villaran MA,
  Santos-Peña M, Maza-Solano JM, Martín-Jimenez DI, Palacios-Garcia JM, Fernandez-Velez C,
  Gonzalez-Garcia J, Sanchez-Calvo JM, Solanellas-Soler J, Sanchez-Gomez S. Loss of Smell and
  Taste Can Accurately Predict COVID-19 Infection: A Machine-Learning Approach. J Clin Med Res
  2021 Feb 3;10(4). PMID:33546319
- Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L,
  Emperador D, Dittrich S, Domen J, Horn SRA, Van den Bruel A, Cochrane COVID-19 Diagnostic
  Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or
  hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020 Jul
  7;7(7):CD013665. PMID:32633856
- 534 31. Ellen Fragaszy, Madhumita Shrotri, Cyril Geismar, Anna Aryee, Sarah Beale, Isobel Braithwaite,
  535 Thomas Byrne, Max T. Eyre, Wing Lam Erica Fong, Jo Gibbs, Pia Hardelid, Jana Kovar, Vasileios
  536 Lampos, Eleni Nastouli, Annalan M.D. Navaratnam, Vincent Nguyen, Parth Patel, Robert W.
  537 Aldridge, Andrew Hayward, Virus Watch Collaborative. Symptom profiles and accuracy of clinical
  538 case definitions for COVID-19 in a community cohort: results from the Virus Watch study [version
  539 1; peer review: awaiting peer review]. 2022. Available from:
- 540 https://wellcomeopenresearch.org/articles/7-84 [accessed Apr 7, 2023]
- Standard States, September 2021Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies United States, September 2021February 2022. MMWR Morb Mortal Wkly Rep 2022 Apr 29;71(17):606–608. PMID:35482574
- Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, Ip P, Fong DYT, Wong WHS,
  Chan SHS, Chan JFW, Peiris M, Lau YL, Rosa Duque JS. Severity of SARS-CoV-2 Omicron BA.2
  infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza
  infections. Emerg Microbes Infect 2022 Dec;11(1):1742–1750. PMID:35730665
- 548 34. Krutikov M, Stirrup O, Nacer-Laidi H, Azmi B, Fuller C, Tut G, Palmer T, Shrotri M, Irwin-Singer
  549 A, Baynton V, Hayward A, Moss P, Copas A, Shallcross L, COVID-19 Genomics UK consortium.
  550 Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England
  551 (VIVALDI): a prospective, cohort study. Lancet Healthy Longev 2022 May;3(5):e347–e355.
  552 PMID:35531432
- 553 35. Mancilla-Galindo J, Kammar-García A, Martínez-Esteban A, Meza-Comparán HD, Mancilla-

- Ramírez J, Galindo-Sevilla N. COVID-19 patients with increasing age experience differential time
  to initial medical care and severity of symptoms. Epidemiol Infect 2021 Oct 22;149:e230.
  PMID:34674789
- 36. Marin-Gomez FX, Mendioroz-Peña J, Mayer M-A, Méndez-Boo L, Mora N, Hermosilla E, Coma E,
  Vilaseca J-M, Leis A, Medina M, Miró Catalina Q, Vidal-Alaball J. Comparing the Clinical
  Characteristics and Mortality of Residential and Non-Residential Older People with COVID-19:
  Retrospective Observational Study. Int J Environ Res Public Health 2022 Jan 2;19(1).
  PMID:35010742
- Tam EMYY, Kwan YK, Ng YY, Yam PW. Clinical course and mortality in older patients with
  COVID-19: a cluster-based study in Hong Kong. Hong Kong Med J 2022 Jun;28(3):215–222.
  PMID:35686472
- 38. Patgiri PR, Rajendran V, Ahmed AB. Clinico-Epidemiological Profiles of COVID-19 Elderly
  Patients in Guwahati City, Assam, India: A Cross-Sectional Study. Cureus 2022 Apr;14(4):e24043.
  PMID:35573552
- 39. Almayahi ZK, Raveendran AV, Al Malki R, Safwat A, Al Baloshi M, Abbas A, Al Salami AS, Al Mujaini SM, Al Dhuhli K, Al Mandhari S. Clinical features, laboratory characteristics and risk factors for mortality of COVID-19 patients in a secondary hospital in Oman during the first wave of the SARS-CoV-2 pandemic. Bull Natl Salmon Resour Cent 2022 May 16;46(1):139.
  PMID:35601475
- 40. Ryan C, Minc A, Caceres J, Balsalobre A, Dixit A, Ng BK, Schmitzberger F, Syed-Abdul S, Fung
  C. Predicting severe outcomes in Covid-19 related illness using only patient demographics,
  comorbidities and symptoms. Am J Emerg Med 2021 Jul;45:378–384. PMID:33046294
- 41. Cuadros DF, Moreno CM, Musuka G, Miller FD, Coule P, MacKinnon NJ. Association Between
  Vaccination Coverage Disparity and the Dynamics of the COVID-19 Delta and Omicron Waves in
  the US. Front Med 2022 Jun 14;9:898101. PMID:35775002
- 42. Kwok KO, Cowling B, Wei V, Riley S, Read JM. Temporal variation of human encounters and the number of locations in which they occur: a longitudinal study of Hong Kong residents. J R Soc
  581 Interface 2018 Jan;15(138). PMID:29367241
- 43. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, Yee NTS, Liu C, Nerurkar SN, Kai JCY, Teng
  MLP, Li X, Zeng H, Borghi JA, Henry L, Cheung R, Nguyen MH. Epidemiology of COVID-19: A
  systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med
  Virol 2021 Mar;93(3):1449–1458. PMID:32790106
- 586 44. Kwok KO, McNeil EB, Tsoi MTF, Wei VWI, Wong SYS, Tang JWT. Will achieving herd
  587 immunity be a road to success to end the COVID-19 pandemic? J Infect 2021 Sep;83(3):381–412.
  588 PMID:34118274

Characteristic	Overall N = 76,762	Wild type N = 1,175	Delta N = 284	Omicron (BA.1) N = 305	Omicron (BA.2) N = 74,685	Omicron (BA.4) N = 63	Omicron (BA.5) N = 250
Age group (years)							
0-9	4,397 (5.7)	33 (2.8)	12 (4.2)	9 (3.0)	4,332 (5.8)	0 (0.0)	11 (4.4)
10-19	3,649 (4.8)	172 (14.6)	17 (6.0)	19 (6.2)	3,415 (4.6)	4 (6.3)	22 (8.8)
20-29	11,785 (15.4)	280 (23.8)	35 (12.3)	77 (25.2)	11,337 (15.2)	14 (22.2)	42 (16.8)
30-39	17,046 (22.2)	249 (21.2)	29 (10.2)	63 (20.7)	16,645 (22.3)	3 (4.8)	57 (22.8)
40-49	15,015 (19.6)	134 (11.4)	44 (15.5)	71 (23.3)	14,704 (19.7)	13 (20.6)	49 (19.6)
50-59	13,148 (17.1)	146 (12.4)	33 (11.6)	38 (12.5)	12,876 (17.2)	13 (20.6)	42 (16.8)
60-69	7,463 (9.7)	109 (9.3)	46 (16.2)	20 (6.6)	7,263 (9.7)	10 (15.9)	15 (6.0)
70+	4,259 (5.5)	52 (4.4)	68 (23.9)	8 (2.6)	4,113 (5.5)	6 (9.5)	12 (4.8)
Sex							
Female	40,968 (53.4)	543 (46.2)	154 (54.2)	155 (50.8)	39,954 (53.5)	27 (42.9)	135 (54.0)
Male	35,794 (46.6)	632 (53.8)	130 (45.8)	150 (49.2)	34,731 (46.5)	36 (57.1)	115 (46.0)
Wave							
1-2	1,175 (1.5)	1,175 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
5	75,587 (98.5)	0 (0.0)	284 (100.0)	305 (100.0)	74,685 (100.0)	63 (100.0)	250 (100.0)
Classification <sup>a</sup>							
Imported <sup>b</sup>	3,265 (4.3)	770 (65.5)	14 (4.9)	304 (99.7)	2,061 (2.8)	30 (47.6)	86 (34.4)
Local	73,497 (95.7)	405 (34.5)	270 (95.1)	1 (0.3)	72,624 (97.2)	33 (52.4)	164 (65.6)
Vaccination status <sup>c</sup>							
Unvaccinated	14,001 (18.2)	1,175 (100.0)	95 (33.5)	38 (12.5)	12,677 (17.0)	3 (4.8)	13 (5.2)
One complete dose	4,453 (5.8)	0 (0.0)	31 (10.9)	8 (2.6)	4,411 (5.9)	0 (0.0)	3 (1.2)
One incomplete dose	2,002 (2.6)	0 (0.0)	6 (2.1)	0 (0.0)	1,996 (2.7)	0 (0.0)	0 (0.0)
Two complete doses	38,425 (50.1)	0 (0.0)	130 (45.8)	183 (60.0)	38,057 (51.0)	11 (17.5)	44 (17.6)
One complete and one incomplete dose	1,473 (1.9)	0 (0.0)	1 (0.4)	0 (0.0)	1,472 (2.0)	0 (0.0)	0 (0.0)
Three complete doses	12,898 (16.8)	0 (0.0)	15 (5.3)	69 (22.6)	12,578 (16.8)	48 (76.2)	188 (75.2)
Two complete and one incomplete doses	3,510 (4.6)	0 (0.0)	6 (2.1)	7 (2.3)	3,494 (4.7)	1 (1.6)	2 (0.8)
Presence of symptoms							
No	22,312 (29.1)	302 (25.7)	72 (25.4)	131 (43.0)	21,690 (29.0)	32 (50.8)	85 (34.0)

## Table 1. Demographic and epidemiological characteristics of all included COVID-19 cases.

<sup>a</sup> Local cases consist of "local cases", "locally acquired cases", "possibly local cases", and "close contact of (possibly) local cases". Others were grouped as imported cases.

<sup>b</sup> The majority of imported cases were from the United Kingdom (13.4%), the United States (7.7%), and Singapore (4.4%).

<sup>c</sup> A complete dose refers to receipt of a vaccine dose given at least 14 days before the symptom onset date (for symptomatic cases) or the report date (for asymptomatic cases).

medRxiv preprint doi: https://doi.org/10.1101/2023.05.25.23289996; this version posted May 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4,0 International license. Table 2. Association of symptoms with death among unvaccinated symptomatic cases

		Frequency		Logistic regression		
Symptom	<b>Overall</b> (N=7,988)	Alive Dead (N=7,913) (N=75)		OR	95% CI	
General symptoms						
Chills	258 (3.2%)	257 (3.2%)	1 (1.3%)	0.68	0.04	3.31
Fatigue	251 (3.1%)	249 (3.1%)	2 (2.7%)	0.58	0.09	2.03
Fever	5,080 (63.6%)	5,032 (63.6%)	48 (64.0%)	2.04	1.22	3.47
Malaise	41 (0.5%)	40 (0.5%)	1 (1.3%)	2.06	0.11	12.0
Nervous system				1		
Disturbance of taste and/or smell	104 (1.3%)	103 (1.3%)	1 (1.3%)	5.85	0.31	31.6
Dizziness	145 (1.8%)	144 (1.8%)	1 (1.3%)	0.78	0.04	4.07
Headache	758 (9.5%)	756 (9.6%)	2 (2.7%)	0.39	0.06	1.33
Respiratory system	I			1	1	1
Blocked nose	139 (1.7%)	138 (1.7%)	1 (1.3%)	3.67	0.20	19.1
Chest pain	262 (3.3%)	261 (3.3%)	1 (1.3%)	0.43	0.02	2.13
Cough	3,350 (41.9%)	3,322 (42.0%)	28 (37.3%)	0.51	0.30	0.84
Runny nose	1,162 (14.5%)	1,157 (14.6%)	5 (6.7%)	0.53	0.18	1.25
Shortness of breath	538 (6.7%)	519 (6.6%)	19 (25.3%)	2.25	1.21	4.03
Sputum (expectoration)	417 (5.2%)	415 (5.2%)	2 (2.7%)	0.38	0.06	1.28
Digestive system	I			1	1	1
Abdominal pain	66 (0.8%)	65 (0.8%)	1 (1.3%)	4.28	0.21	27.6
Nausea or vomiting	332 (4.2%)	327 (4.1%)	5 (6.7%)	2.04	0.64	5.31
Sore throat	2,232 (27.9%)	2,224 (28.1%)	8 (10.7%)	0.43	0.19	0.87
Musculoskeletal system	1				1	1
Back pain	30 (0.4%)	29 (0.4%)	1 (1.3%)	14.2	0.73	86.0
Unspecified muscle pain	235 (2.9%)	234 (3.0%)	1 (1.3%)	0.71	0.04	3.42

Remarks: All models were adjusted for age, sex, subvariant, and reporting delay.

medRxiv preprint doi: https://doi.org/10.1101/2023.05.25.23289996; this version posted May 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **Table 3.** Average penalized LASSO estimates for symptoms associated with death and stepwise generalized

linear models among unvaccinated elderly cases

	A	All Elderly n=1,852	Omicron (BA.2) n=1,721		
	LASSO GLM		LASSO	GLM	
	Avg est.	OR (95% CI)	Avg est.	OR (95% CI)	
Predictive symptoms					
Abdominal pain	1.44	6.52 (0.30-44.7)		-	
Blocked nose	1.11	5.24 (0.78-19.9)	1.19	5.34 (0.80-20.1)	
Malaise	0.94	3.31 (0.17-19.7)		-	
Shortness of breath	0.60	2.12 (1.20-3.57)	0.53	2.02 (1.12-3.47)	
Fever (temperature>38°C)	0.32	1.49 (0.99-2.21)	0.23	1.38 (0.90-2.06)	
Protective symptoms					
Cough	-0.79	0.36 (0.21-0.57)	-0.84	0.33 (0.19-0.54)	
Diarrhea	-0.73	-	-0.56	-	
Chest pain	-0.68	0.28 (0.04-0.99)	-0.63	0.30 (0.05-1.04)	
Voice disorders	-0.64	-	-0.72	-	
Sore throat	-0.52	0.43 (0.19-0.86)	-0.48	0.45 (0.20-0.90)	
Loss of appetite	-0.46	-	-0.20	-	
AIC		1218.75		1172.90	
AUC		0.9261		0.9264	

Avg est.: Average estimated coefficient. GLM: generalised linear model. LASSO: least absolute shrinkage and selection operator. Remarks: 1. All models were adjusted for age, sex, presence of chronic diseases, and reporting delay.

2. Dashes indicate that the symptom was excluded in the model due to convergence failure.




Figure 1. Study flowchart




Figure 2. Prevalence of commonly reported symptoms among COVID-19 cases stratified by vaccination status for (A) wild-type, (B) delta and (C) omicron BA.2 variants. Only symptoms with a variant-specific combined (both the vaccinated and unvaccinated) prevalence >1% are shown.




Figure 3. Effect of variant on symptom development among unvaccinated symptomatic cases (adjusting for age, sex, and reporting delay). Estimates that are significant and not significant are represented by solid triangles and circles, respectively.






Figure 4. Effect of the omicron variant compared to delta on symptom development among fully vaccinated symptomatic cases. Solid triangles and circles represent estimates that are significant and not significant. (adjusting for age, sex, and reporting delay).


# Predictive symptoms



## Protective symptoms



## Common symptoms



**Figure 5.** Effect of the number of vaccine doses on symptom development among symptomatic elderly cases, adjusting for age, sex, variant, and reporting delay. The reference group is the unvaccinated cases.




Figure 6. Effect of the time elapsed since the last vaccination on symptom development among symptomatic elderly cases, adjusting for age, sex, variant, and reporting delay. The reference group is the unvaccinated cases.